Tuesday, June 24, 2014

CBT Following Fluoxetine May Reduce Depression Relapse Risk in Youth, Study Shows

Following a course of fluoxetine with cognitive-behavioral therapy (CBT) appears to be effective in reducing the risk of relapse in young people with major depression, according to a report online in AJP in Advance titled “Sequential Treatment With Fluoxetine and Relapse-Prevention CBT to Improve Outcomes in Pediatric Depression.”

Researchers at the University of Texas Southwestern Medical Center and Children’s Medical Center of Dallas randomly assigned youth aged 8 to 17 with major depression who responded well to an initial six weeks of fluoxetine treatment to either continued monotherapy with fluoxetine or continued medication management combined with CBT for six months. Primary outcome measures were time to remission (with remission defined as a score of 28 or less on the Children’s Depression Rating Scale–Revised [CDRS-R]) and rate of relapse (with relapse defined as either a CDRS-R score of 40 or more with a history of two weeks of symptom worsening, or clinical deterioration).

During the 30-week continuation treatment period, time to remission did not differ significantly between treatment groups, but the medication management plus CBT group had a significantly lower risk of relapse than the medication management only group. The estimated probability of relapse by week 30 was 9% with medication management plus CBT and 26.5% with medication management only.

“To our knowledge, this is the first randomized controlled trial of a sequential treatment strategy to prevent relapse in youths with major depressive disorder,” the researchers said. “The results demonstrate that, as in adults, sequencing treatments can reduce risk of relapse and lengthen time to relapse in depressed youths.”

For more information on the use of CBT in youth with depression, see the Psychiatric News article, “CBT Program Helps Some Teens Lower Their Depression Risk.”

(image: hikrcn/shutterstock)


The content of Psychiatric News does not necessarily reflect the views of APA or the editors. Unless so stated, neither Psychiatric News nor APA guarantees, warrants, or endorses information or advertising in this newspaper. Clinical opinions are not peer reviewed and thus should be independently verified.